4//SEC Filing
Nexvet Biopharma plc 4
Accession 0001171000-17-000039
CIK 0001618561operating
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 12:11 PM ET
Size
12.1 KB
Accession
0001171000-17-000039
Insider Transaction Report
Form 4
Heffernan Mark
Chief Executive Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2017-07-01$0.13/sh+25,000$3,125→ 74,167 total - Exercise/Conversion
Ordinary Shares
2017-07-01$0.13/sh+35,643$4,455→ 109,810 total - Exercise/Conversion
Restricted Share Units
2017-07-01−25,000→ 50,000 totalExercise: $0.13From: 2017-07-01Exp: 2020-07-01→ Ordinary Shares (25,000 underlying) - Exercise/Conversion
Restricted Share Units
2017-07-01−35,643→ 106,929 totalExercise: $0.13From: 2017-07-01Exp: 2020-07-01→ Ordinary Shares (35,643 underlying)
Holdings
- 243,587(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
Ordinary Shares
Footnotes (3)
- [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- [F2]25,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
- [F3]35,643 of the Restricted Share Units vested and became convertible on 7/1/17 and 35,643 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
Documents
Issuer
Nexvet Biopharma plc
CIK 0001618561
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001618561
Filing Metadata
- Form type
- 4
- Filed
- Jul 4, 8:00 PM ET
- Accepted
- Jul 5, 12:11 PM ET
- Size
- 12.1 KB